Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.
Founded in late 1997, their US offices are situated in the hub of California’s pharmaceutical and biotech development region. Together with other Actelion subsidiaries in 28 countries around the world, we are focused on the development and commercialization of innovative treatments to serve critical, unmet medical needs. Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.
Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.
Visit Actelion Pharmaceuticals.